{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T02:07:56Z","timestamp":1791338876580,"version":"4.3.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001646","name":"Robert Bosch Stiftung","doi-asserted-by":"publisher","award":["Project O3"],"award-info":[{"award-number":["Project O3"]}],"id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001646","name":"Robert Bosch Stiftung","doi-asserted-by":"publisher","award":["Project O3"],"award-info":[{"award-number":["Project O3"]}],"id":[{"id":"10.13039\/501100001646","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1038\/s41375-025-02794-1","type":"journal-article","created":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T12:12:40Z","timestamp":1762517560000},"page":"2988-2996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Cyclin D1 rearranged diffuse large B-cell lymphoma\u2014an evolving concept"],"prefix":"10.1038","volume":"39","author":[{"given":"K. S.","family":"Kurz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-7966","authenticated-orcid":false,"given":"A.","family":"Zamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5160-4732","authenticated-orcid":false,"given":"C.","family":"Drewes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0729-0245","authenticated-orcid":false,"given":"E.","family":"Madej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5375-7512","authenticated-orcid":false,"given":"C.","family":"Laurent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Burroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Donzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Xerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mescam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Plank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4377-3209","authenticated-orcid":false,"given":"L. M. R.","family":"Gjerdrum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4424-6139","authenticated-orcid":false,"given":"J.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9543-4084","authenticated-orcid":false,"given":"J.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4003-6855","authenticated-orcid":false,"given":"I.","family":"Oschlies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4117","authenticated-orcid":false,"given":"W.","family":"Klapper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Gramlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Doll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Maurus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. M.","family":"Staiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7433-3703","authenticated-orcid":false,"given":"R.","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1017-5045","authenticated-orcid":false,"given":"M-Q.","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rosenwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7990-6793","authenticated-orcid":false,"given":"G.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2933-005X","authenticated-orcid":false,"given":"H.","family":"Horn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,7]]},"reference":[{"key":"2794_CR1","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, Araujo, de Oliveira IB, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022;36:1720\u201348.","journal-title":"Leukemia"},{"key":"2794_CR2","unstructured":"Haematolymphoid Tumours: WHO Classification of Tumours, 5th edn. International Agency for Research on Cancer: Lyon, 2024."},{"key":"2794_CR3","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022;140:1229\u201353. Blood 2023;141:437.","journal-title":"Blood"},{"key":"2794_CR4","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","volume":"140","author":"E Campo","year":"2022","unstructured":"Campo E, Jaffe ES, Cook JR, Quintanilla-Martinez L, Swerdlow SH, Anderson KC, et al. The international consensus classification of mature lymphoid neoplasms: a report from the clinical advisory committee. Blood. 2022;140:1229\u201353.","journal-title":"Blood"},{"key":"2794_CR5","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407.","journal-title":"N Engl J Med"},{"key":"2794_CR6","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","volume":"135","author":"SE Lacy","year":"2020","unstructured":"Lacy SE, Barrans SL, Beer PA, Painter D, Smith AG, Roman E, et al. Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report. Blood. 2020;135:1759\u201371.","journal-title":"Blood"},{"key":"2794_CR7","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R, et al. Molecular subtypes of diffuse large B-cell lymphomas are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390.","journal-title":"Nat Med"},{"key":"2794_CR8","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1182\/blood.2022015854","volume":"140","author":"Leval","year":"2022","unstructured":"Leval, de L, Alizadeh AA, Bergsagel PL, Campo E, Davies A, et al. Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022;140:2193\u2013227.","journal-title":"Blood"},{"key":"2794_CR9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s00428-024-03774-z","volume":"484","author":"J Carreras","year":"2024","unstructured":"Carreras J, Ikoma H, Kikuti YY, Miyaoka M, Hiraiwa S, Tomita S, et al. Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement. Virchows Arch. 2024;484:657\u201376.","journal-title":"Virchows Arch"},{"key":"2794_CR10","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood.V89.4.1421","volume":"89","author":"G Ott","year":"1997","unstructured":"Ott G, Kalla J, Ott MM, Schryen B, Katzenberger T, Muller JG, et al. Blastoid variants of mantle cell lymphoma: Frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood. 1997;89:1421\u20139.","journal-title":"Blood"},{"key":"2794_CR11","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/10428199809059246","volume":"32","author":"G Ott","year":"1998","unstructured":"Ott G, Kalla J, Hanke A, M\u00fcller JG, Rosenwald A, Katzenberger T, et al. The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. Leuk Lymphoma. 1998;32:55\u201363.","journal-title":"Leuk Lymphoma"},{"key":"2794_CR12","doi-asserted-by":"crossref","unstructured":"Chen MY, Rider AB, Ferry JA, Hasserjian RP, Nardi V, Louissaint A Jr, et al. Comparison of Immunohistochemistry With Fluorescence In Situ Hybridization for Assessment of CCND1 Rearrangement in Plasma Cell Myeloma. Am J Surg Pathol. 2025;49:1143\u201349.","DOI":"10.1097\/PAS.0000000000002421"},{"key":"2794_CR13","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1111\/j.1365-2141.1995.tb05429.x","volume":"91","author":"F Bosch","year":"1995","unstructured":"Bosch F, Campo E, Jares P, Pittaluga S, Mu\u00f1oz J, Nayach I, et al. Increased expression of the PRAD-1\/CCND1 gene in hairy cell leukaemia. Br J Haematol. 1995;91:1025\u201330.","journal-title":"Br J Haematol"},{"key":"2794_CR14","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/PAS.0000000000000120","volume":"38","author":"D Juskevicius","year":"2014","unstructured":"Juskevicius D, Ruiz C, Dirnhofer S, Tzankov A. Clinical, morphologic, phenotypic, and genetic evidence of cyclin D1-positive diffuse large B-cell lymphomas with CYCLIN D1 gene rearrangements. Am J Surg Pathol. 2014;38:719\u201327.","journal-title":"Am J Surg Pathol"},{"key":"2794_CR15","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1309\/AJCPUIDW2CPTA1JA","volume":"143","author":"M Al-Kawaaz","year":"2015","unstructured":"Al-Kawaaz M, Mathew S, Liu Y, Gomez ML, Chaviano F, Knowles DM, et al. Cyclin D1-positive diffuse large B-cell lymphoma with IGH-CCND1 translocation and BCL6 rearrangement: a report of two cases. Am J Clin Pathol. 2015;143:288\u201399.","journal-title":"Am J Clin Pathol"},{"key":"2794_CR16","doi-asserted-by":"crossref","first-page":"e505","DOI":"10.1097\/HS9.0000000000000505","volume":"5","author":"J Cheng","year":"2021","unstructured":"Cheng J, Hashem MA, Barab\u00e9 F, Cloutier S, Xi L, Raffeld M, et al. CCND1 genomic rearrangement as a secondary event in high grade B-cell lymphoma. HemaSphere. 2021;5:e505.","journal-title":"HemaSphere"},{"key":"2794_CR17","volume":"7","author":"G Da","year":"2019","unstructured":"Da G, Liu Z. Cyclin D1 + large B-cell lymphoma with altered CCND1 and BCL-6 rearrangements: a diagnostic challenge. Biomark Res. 2019;7:11.","journal-title":"Biomark Res"},{"key":"2794_CR18","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1002\/hon.2779","volume":"38","author":"AM Parrott","year":"2020","unstructured":"Parrott AM, Haggiagi AM, Murty VV, Bhagat G, Alobeid B. Primary large B-cell lymphoma of the central nervous system with cyclin D1 expression and t(11;14) (IGH-CCND1): Diffuse large B-cell lymphoma with CCND1 rearrangement or mantle cell lymphoma?. Hematol Oncol. 2020;38:817\u201322.","journal-title":"Hematol Oncol"},{"key":"2794_CR19","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12308-024-00593-8","volume":"17","author":"F Monika","year":"2024","unstructured":"Monika F, Sabri A, Cantu D, Vail E, Siref A. Molecular characterization of a rare case of high-grade B-cell lymphoma with MYC, BCL2, BCL6, and CCND1 rearrangements. J Hematop. 2024;17:155\u201361.","journal-title":"J Hematop"},{"key":"2794_CR20","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-024-01146-z","volume":"14","author":"E \u00d6zo\u011ful","year":"2024","unstructured":"\u00d6zo\u011ful E, Montaner A, Pol M, Frigola G, Balagu\u00e9 O, Syrykh C, et al. Large B-cell lymphomas with CCND1 rearrangement have different immunoglobulin gene breakpoints and genomic profile than mantle cell lymphoma. Blood Cancer J. 2024;14:166.","journal-title":"Blood Cancer J"},{"key":"2794_CR21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","volume":"9","author":"M Pfreundschuh","year":"2008","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60). Lancet Oncol. 2008;9:105\u201316.","journal-title":"Lancet Oncol"},{"key":"2794_CR22","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.2013.51.4505","volume":"32","author":"G Held","year":"2014","unstructured":"Held G, Murawski N, Ziepert M, Fleckenstein J, P\u00f6schel V, Zwick C, et al. Role of radiotherapy to bulky disease in elderly patients with aggressive B-cell lymphoma. J Clin Oncol. 2014;32:1112\u20138.","journal-title":"J Clin Oncol"},{"key":"2794_CR23","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1093\/annonc\/mdu208","volume":"25","author":"N Murawski","year":"2014","unstructured":"Murawski N, Pfreundschuh M, Zeynalova S, Poeschel V, H\u00e4nel M, Held G, et al. Optimization of rituximab for the treatment of DLBCL (I): Dose-dense rituximab in the DENSE-R-CHOP-14 trial of the DSHNHL. Ann Oncol. 2014;25:1800\u20136.","journal-title":"Ann Oncol"},{"key":"2794_CR24","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1200\/JCO.2013.54.6861","volume":"32","author":"M Pfreundschuh","year":"2014","unstructured":"Pfreundschuh M, Poeschel V, Zeynalova S, H\u00e4nel M, Held G, Schmitz N, et al. Optimization of rituximab for the treatment of diffuse large B-cell lymphoma (II): Extended rituximab exposure time in the SMARTE-R-CHOP-14 trial of the german high-grade non-Hodgkin lymphoma study group. J Clin Oncol. 2014;32:4127\u201333.","journal-title":"J Clin Oncol"},{"key":"2794_CR25","first-page":"1013","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh M, Kuhnt E, Tr\u00fcmper L, Osterborg A, Trneny M, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. The Lancet. Oncology. 2011;12:1013\u201322.","journal-title":"Oncology"},{"key":"2794_CR26","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.15710","volume":"184","author":"B Friedrichs","year":"2019","unstructured":"Friedrichs B, Nickelsen M, Ziepert M, Altmann B, Haenel M, Viardot A, et al. Doubling rituximab in high-risk patients with aggressive B-cell lymphoma -results of the DENSE-R-MegaCHOEP trial. Br J Haematol. 2019;184:760\u20138.","journal-title":"Br J Haematol"},{"key":"2794_CR27","doi-asserted-by":"crossref","first-page":"7574","DOI":"10.1200\/JCO.2018.36.15_suppl.7574","volume":"36","author":"M Pfreundschuh","year":"2018","unstructured":"Pfreundschuh M, Murawski N, Ziepert M, Altmann B, Dreyling MH, Borchmann P, et al. Radiotherapy (RT) to bulky (B) and extralymphatic (E) disease in combination with 6xR-CHOP-14 or R-CHOP-21 in young good-prognosis DLBCL patients: Results of the 2x2 randomized UNFOLDER trial of the DSHNHL\/GLA. J Clin Oncol. 2018;36:7574.","journal-title":"J Clin Oncol"},{"key":"2794_CR28","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-25405-w","volume":"12","author":"F Frontzek","year":"2021","unstructured":"Frontzek F, Staiger AM, Zapukhlyak M, Xu W, Bonzheim I, Borgmann V, et al. Molecular and functional profiling identifies therapeutically targetable vulnerabilities in plasmablastic lymphoma. Nat Commun. 2021;12:1413.","journal-title":"Nat Commun"},{"key":"2794_CR29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275\u201382.","journal-title":"Blood"},{"key":"2794_CR30","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","volume":"121","author":"H Horn","year":"2013","unstructured":"Horn H, Ziepert M, Becher C, Barth TFE, Bernd H-W, Feller AC, et al. MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood. 2013;121:2253\u201363.","journal-title":"Blood"},{"key":"2794_CR31","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2015.43","volume":"29","author":"H Horn","year":"2015","unstructured":"Horn H, Ziepert M, Wartenberg M, Staiger AM, Barth TFE, Bernd H-W, et al. Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma. Leukemia. 2015;29:1564\u201370.","journal-title":"Leukemia"},{"key":"2794_CR32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/s41375-019-0573-y","volume":"34","author":"AM Staiger","year":"2020","unstructured":"Staiger AM, Altenbuchinger M, Ziepert M, Kohler C, Horn H, Huttner M, et al. A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL. Leukemia. 2020;34:543\u201352.","journal-title":"Leukemia"},{"key":"2794_CR33","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","volume":"72","author":"A Navarro","year":"2012","unstructured":"Navarro A, Clot G, Royo C, Jares P, Hadzidimitriou A, Agathangelidis A, et al. Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res. 2012;72:5307\u201316.","journal-title":"Cancer Res"},{"key":"2794_CR34","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1101\/gad.7.5.812","volume":"7","author":"V Baldin","year":"1993","unstructured":"Baldin V, Lukas J, Marcote MJ, Pagano M, Draetta G. Cyclin D1 is a nuclear protein required for cell cycle progression in G1. Genes Dev. 1993;7:812\u201321.","journal-title":"Genes Dev"},{"key":"2794_CR35","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1002\/cncr.28664","volume":"120","author":"CY Ok","year":"2014","unstructured":"Ok CY, Xu-Monette ZY, Tzankov A, O\u2019Malley DP, Montes-Moreno S, Visco C, et al. Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program. Cancer. 2014;120:1818\u201329.","journal-title":"Cancer"},{"key":"2794_CR36","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/10428194.2010.540361","volume":"52","author":"T Vela-Ch\u00c1vez","year":"2011","unstructured":"Vela-Ch\u00c1vez T, Adam P, Kremer M, Bink K, Bacon CM, Menon G, et al. Cyclin D1 positive diffuse large B-cell lymphoma is a post-germinal center-type lymphoma without alterations in the CCND1 gene locus. Leuk Lymphoma. 2011;52:458\u201366.","journal-title":"Leuk Lymphoma"},{"key":"2794_CR37","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1532\/IJH97.03105","volume":"79","author":"K Kawakami","year":"2004","unstructured":"Kawakami K, Miyanishi S, Sonoki T, Nakamura S, Nomura K, Murata T, et al. Case of B-cell lymphoma with rearrangement of the BCL1, BCL2, BCL6, and c-MYC genes. Int J Hematol. 2004;79:474\u20139.","journal-title":"Int J Hematol"},{"key":"2794_CR38","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1111\/pin.12335","volume":"65","author":"M Yoshida","year":"2015","unstructured":"Yoshida M, Ichikawa A, Miyoshi H, Kiyasu J, Kimura Y, Arakawa F, et al. Clinicopathological features of double-hit B-cell lymphomas with MYC and BCL2, BCL6 or CCND1 rearrangements. Pathol Int. 2015;65:519\u201327.","journal-title":"Pathol Int"},{"key":"2794_CR39","volume":"5","author":"A Ittel","year":"2015","unstructured":"Ittel A, H\u00e9lias C, Wissler MP, Toussaint E, Miguet L, Chenard MP, et al. Four genetic lymphoma-specific events (MYC, BCL2, BCL6 and CCND1) identified in a high grade B lymphoma case. Blood ancer J. 2015;5:e374.","journal-title":"Blood ancer J"},{"key":"2794_CR40","doi-asserted-by":"crossref","first-page":"2672","DOI":"10.3109\/10428194.2016.1153085","volume":"57","author":"I Schliemann","year":"2016","unstructured":"Schliemann I, Oschlies I, Nagel I, Maria Murga Penas E, Siebert R, Sander B. The t(11;14)(q13;q32)\/CCND1-IGH translocation is a recurrent secondary genetic aberration in relapsed chronic lymphocytic leukemia. Leuk lymphoma. 2016;57:2672\u20136.","journal-title":"Leuk lymphoma"},{"key":"2794_CR41","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/ejh.12119","volume":"91","author":"Y Nishida","year":"2013","unstructured":"Nishida Y, Takeuchi K, Tsuda K, Ugai T, Sugihara H, Yamakura M, et al. Acquisition of t(11;14) in a patient with chronic lymphocytic leukemia carrying both t(14;19)(q32;q13.1) and +12. Eur J Haematol. 2013;91:179\u201382.","journal-title":"Eur J Haematol"},{"key":"2794_CR42","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cancergen.2015.03.007","volume":"208","author":"PR Koduru","year":"2015","unstructured":"Koduru PR, Chen W, Garcia R, Fuda F. Acquisition of a t(11;14)(q13;q32) in clonal evolution in a follicular lymphoma with a t(14;18)(q32;q21) and t(3;22)(q27;q11.2). Cancer Genet. 2015;208:303\u20139.","journal-title":"Cancer Genet"},{"key":"2794_CR43","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","volume":"94","author":"A Mozos","year":"2009","unstructured":"Mozos A, Royo C, Hartmann E, de Jong D, Baro C, Valera A, et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica. 2009;94:1555\u201362.","journal-title":"Haematologica"},{"key":"2794_CR44","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1182\/blood-2007-06-093401","volume":"111","author":"S Ek","year":"2008","unstructured":"Ek S, Dictor M, Jerkeman M, Jirstr\u00f6m K, Borrebaeck CAK. Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma. Blood. 2008;111:800\u20135.","journal-title":"Blood"},{"key":"2794_CR45","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1309\/AJCPV8LN5ENMZOVY","volume":"132","author":"J Gao","year":"2009","unstructured":"Gao J, Peterson L, Nelson B, Goolsby C, Chen Y-H. Immunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol. 2009;132:699\u2013706.","journal-title":"Am J Clin Pathol"},{"key":"2794_CR46","doi-asserted-by":"crossref","first-page":"e782","DOI":"10.1016\/j.clml.2020.05.003","volume":"20","author":"Y Xu","year":"2020","unstructured":"Xu Y, Sun W, Li F. De novo CD5+ diffuse large B-cell lymphoma: biology, mechanism, and treatment advances. Clin Lymphoma Myeloma Leuk. 2020;20:e782\u2013e790.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2794_CR47","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1182\/blood.2020005289","volume":"136","author":"F Nadeu","year":"2020","unstructured":"Nadeu F, Martin-Garcia D, Clot G, D\u00edaz-Navarro A, Duran-Ferrer M, Navarro A, et al. Genomic and epigenomic insights into the origin, pathogenesis, and clinical behavior of mantle cell lymphoma subtypes. Blood. 2020;136:1419\u201332.","journal-title":"Blood"},{"key":"2794_CR48","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1182\/blood-2003-05-1383","volume":"102","author":"D Kienle","year":"2003","unstructured":"Kienle D, Kr\u00f6ber A, Katzenberger T, Ott G, Leupolt E, Barth TFE, et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood. 2003;102:3003\u20139.","journal-title":"Blood"},{"key":"2794_CR49","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.ajpath.2012.07.028","volume":"181","author":"E Sebasti\u00e1n","year":"2012","unstructured":"Sebasti\u00e1n E, Alcoceba M, Balanzategui A, Mar\u00edn L, Montes-Moreno S, Flores T, et al. Molecular characterization of immunoglobulin gene rearrangements in diffuse large B-cell lymphoma. Am J Pathol. 2012;181:1879\u201388.","journal-title":"Am J Pathol"},{"key":"2794_CR50","doi-asserted-by":"crossref","first-page":"18250","DOI":"10.1073\/pnas.1314608110","volume":"110","author":"S Bea","year":"2013","unstructured":"Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013;110:18250\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2794_CR51","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/35085588","volume":"412","author":"L Pasqualucci","year":"2001","unstructured":"Pasqualucci L, Neumeister P, Goossens T, Nanjangud G, Chaganti RS, K\u00fcppers R, et al. Hypermutation of multiple proto-oncogenes in B-cell diffuse large-cell lymphomas. Nature. 2001;412:341\u20136.","journal-title":"Nature"},{"key":"2794_CR52","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1053\/j.seminoncol.2016.02.012","volume":"43","author":"D Rossi","year":"2016","unstructured":"Rossi D, Gaidano G. Richter syndrome: pathogenesis and management. Semin Oncol. 2016;43:311\u20139.","journal-title":"Semin Oncol"},{"key":"2794_CR53","doi-asserted-by":"publisher","unstructured":"George GV, Adlowitz DG, Okeson KR, Jelloul FZ, Fang H, Wang W, et al. Cyclin-D1 rearrangement as a secondary event in the large cell transformation of splenic marginal zone lymphoma with a TP53 deletion. Virchows Archiv. 2024. https:\/\/doi.org\/10.1007\/s00428-024-03946-x.","DOI":"10.1007\/s00428-024-03946-x"},{"key":"2794_CR54","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.prp.2012.12.001","volume":"209","author":"A Delas","year":"2013","unstructured":"Delas A, Sophie D, Brousset P, Laurent C. Unusual concomitant rearrangements of Cyclin D1 and MYC genes in blastoid variant of mantle cell lymphoma: case report and review of literature. Pathol, Res Pract. 2013;209:115\u20139.","journal-title":"Pathol, Res Pract"},{"key":"2794_CR55","doi-asserted-by":"crossref","DOI":"10.1016\/j.humpath.2025.105793","volume":"159","author":"G Tang","year":"2025","unstructured":"Tang G, Jain P, Hu S, Ok CY, Wang WJ, Quesada AE, et al. Optical genome mapping reveals diverse mechanisms of cyclin activation in mantle cell lymphomas lacking IGH:CCND1. Hum Pathol. 2025;159:105793.","journal-title":"Hum Pathol"},{"key":"2794_CR56","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.3324\/haematol.2019.237073","volume":"105","author":"C Fuster","year":"2020","unstructured":"Fuster C, Mart\u00edn-Garcia D, Balagu\u00e9 O, Navarro A, Nadeu F, Costa D, et al. Cryptic insertions of the immunoglobulin light chain enhancer region near CCND1 in t(11;14)-negative mantle cell lymphoma. Haematologica. 2020;105:e408\u2013e411.","journal-title":"Haematologica"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02794-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02794-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02794-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:10:54Z","timestamp":1763629854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02794-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,7]]},"references-count":56,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2794"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02794-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,7]]},"assertion":[{"value":"18 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Clinical trials were conducted in accordance with the Helsinki declaration, and the protocols had been approved by the ethics review committee of each participating centre. Within these clinical trials, all patients had given informed consent. For those patients not enrolled in these trials, informed consent had been waived by the local ethics committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}